Previous 10 | Next 10 |
MONROVIA, Calif. , Feb. 20, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the U.S. Food and ...
MONROVIA, Calif. , Feb. 19, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it will re...
MONROVIA, Calif. , Feb. 7, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company man...
Thinly traded Xencor ( XNCR +3.5% ) is up below-average volume in response to its license agreement with Roche's ( OTCQX:RHHBY +0.6% ) Genentech aimed at developing and commercializing novel IL-15 cytokine therapeutics, including XNCR's XmAb24306. More news on: Xencor, Inc., Roche Ho...
MONROVIA, Calif. , Feb. 5, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease, and cancer, today announced it has entered into a ...
Forensic Value Stock Selections The following stock selections using three forensic algorithms from the financial literature rely exclusively on fundamental data and year-over-year operational performance measures. The combination of all three bankruptcy and financial irregularity algorithms...
NEW YORK, Jan. 28, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ONEOK, Inc. (NYSE:OKE), Alaska Air Group, Inc. (NYSE:ALK), Comcast Corpor...
MONROVIA, Calif. , Jan. 7, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease and cancer, today announced it will regain rights to dev...
MONROVIA, Calif. , Nov. 20, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat...
Xencor (NASDAQ: XNCR ) Q3 results ($M): Revenues: 29.0 (from Novartis collaboration and $9M in milestone payments from Alexion). More news on: Xencor, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through ...
2024-06-04 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...